Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy |
| |
Authors: | Ritsuko Katafuchi Tetsuya Kawamura Kensuke Joh Akinori Hashiguchi Satoshi Hisano Akira Shimizu Yoichi Miyazaki Masaharu Nagata Seiichi Matsuo The IgA nephropathy Study Group in Japan |
| |
Affiliation: | 1.Kidney Unit,National Fukuoka-Higashi Medical Center,Koga-City,Japan;2.Division of Kidney and Hypertension, Department of Internal Medicine,Jikei University School of Medicine,Tokyo,Japan;3.Department of Pathology,Tohoku University Graduate School of Medicine,Sendai,Japan;4.Department of Pathology,Keio University School of Medicine,Tokyo,Japan;5.Department of Pathology, Faculty of Medicine,Fukuoka University,Fukuoka,Japan;6.Department of Pathology,Nihon University School of Medicine,Tokyo,Japan;7.Department of Medicine and Clinical Science, Graduate School of Medical Science,Kyushu University,Fukuoka,Japan;8.Division of Nephrology, Department of Internal Medicine,University of Nagoya,Nagoya,Japan |
| |
Abstract: |
BackgroundThe IgA nephropathy (IgAN) Study Group in Japan conducted a multicenter, randomized, controlled trial of tonsillectomy with steroid pulse therapy (TSP) versus steroid pulse monotherapy in patients with IgAN (UMIN Clinical Trial Registry Number; C000000384). The effects of therapies in relation to pathological severity were analyzed in this study.MethodsThe patients with IgAN, urinary protein 1.0–3.5 g/day, serum creatinine of 1.5 mg/dl or less were randomly assigned to receiving TSP (Group A) or steroid pulses alone (Group B). The primary endpoint was the disappearance of proteinuria and/or hematuria. Twenty-six biopsies in Group A and 33 in Group B were available. The histological grades (HG) according to the percentage of glomeruli with crescent or sclerosis and the Oxford classification were analyzed.ResultsThe patients in Group A had a 4.32- to 12.1-fold greater benefit of disappearance of proteinuria and 3.61- to 8.17-fold greater benefit of clinical remission (disappearance of proteinuria and hematuria) than those in Group B in patients with HG2–3, acute lesions (cellular or fibrocellular crescent) affecting more than 5 % of glomeruli, chronic lesions (fibrous crescents or sclerosis) affecting more than 20 % and S1. In contrast, odds ratios for disappearance of proteinuria or clinical remission in Group A to Group B were not significant in patients with HG 1, acute lesion in 5 % or less of glomeruli, chronic lesion in 20 % or less and S0. The disappearance of hematuria showed no relation to pathological severity.ConclusionTSP might be better employed according to the pathological severity. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|